General MedicationsInjectionStandard
LOARGYS
PEGZILARGINASE-NBLN
Standard Dose
0.1MG/KG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview LOARGYS is listed in Drugs@FDA under application 761211 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient PEGZILARGINASE-NBLN Form and strength Injectable; Injection - 0.1MG/KG Sponsor IMMEDICA PHARMA AB Submission history Latest submission status date: 2026-02-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview LOARGYS is listed in Drugs@FDA under application 761211 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient PEGZILARGINASE-NBLN Form and strength Injectable; Injection - 0.1MG/KG Sponsor IMMEDICA PHARMA AB Submission history Latest submission status date: 2026-02-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.